查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1420415

全球带状疱疹疫苗市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按产品类型、按免疫类型、按地区

Shingles Vaccine Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日期: | 出版商: Fairfield Market Research | 英文 250 Pages | 商品交期: 2-5个工作天内

价格
简介目录

全球带状疱疹疫苗市场正在经历显着成长，预计到 2024 年将达到约 46 亿美元。预计未来 10 年该市场将以 16% 的复合年增长率成长，到 2031 年底将达到 130 亿美元。

国家生物技术资讯中心强调带状疱疹疫苗在预防带状疱疹传播方面的关键作用。现有的针对带状疱疹后神经痛（PHN）的抗病毒治疗并不完全有效，特别是对于免疫功能低下的患者，这增加了疫苗开发的紧迫性。

由于免疫系统较弱，60岁以上的老年人特别容易感染带状疱疹。美国疾病管制与预防中心 (CDC) 报告称，全球带状疱疹病例中有一半发生在这个年龄段，这凸显了对安全且具有成本效益的带状疱疹疫苗的需求。虽然带状疱疹并不致命，但它可能导致肺炎和脑炎等健康併发症，因此疫苗对该族群至关重要。

带状疱疹的盛行率因地区和气候条件而异。带状疱疹由水痘带状疱疹病毒引起，在热带和亚热带地区很常见。欠发达国家，特别是热带亚洲国家，缺乏常规水痘疫苗接种，这为带状疱疹疫苗市场创造了机会。将带状疱疹疫苗接种规划纳入世卫组织区域免疫战略计划，可以显着减轻欠发达地区的疾病负担和相关併发症。

本报告研究了全球带状疱疹疫苗市场，并提供了市场概况，包括按产品类型、免疫类型、区域趋势以及进入市场的公司的竞争趋势划分的趋势。

目录

第一章执行摘要

第二章市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第三章 2018-2031年全球带状疱疹疫苗市场展望

  • 全球带状疱疹疫苗市场展望，按产品类型、价值（十亿美元），2018-2031 年
  • 全球带状疱疹疫苗市场展望，按免疫类型、价值（十亿美元），2018-2031
  • 全球带状疱疹疫苗市场展望，按地区，价值（十亿美元），2018-2031

第四章 2018-2031 年北美带状疱疹疫苗市场展望

第五章欧洲带状疱疹疫苗市场展望，2018-2031

第六章 2018-2031 年亚太地区带状疱疹疫苗市场展望

第七章 2018-2031 年拉丁美洲带状疱疹疫苗市场展望

第八章 2018-2031 年中东和非洲带状疱疹疫苗市场展望

第9章 竞争格局

  • 按产品和疫苗接种类型划分的热图
  • 2023 年公司市场份额分析
  • 比赛仪表板
  • 公司简介
    • GlaxoSmithKline plc.
    • Merck & Co., Inc.
    • SK Chemicals
    • Green Cross Corp
    • Geneone Life Science
    • Vaccitech
    • CanSinoBIO
    • Cipla Inc.
    • Pfizer Inc

第10章附录

简介目录

The global Shingles Vaccine market is experiencing significant growth, with a valuation of approximately US$ 4.6 billion in 2024. According to the latest report by Fairfield Market Research, the market is poised to achieve a staggering CAGR of 16% over the next decade, reaching an estimated US$ 13 billion by the end of 2031.

Sales Analysis and Market Outlook

Fairfield Market Research reveals that the Shingles vaccine segment exhibited the highest revenue share during the forecasted period. The recombinant vaccine, within the vaccine type segment, dominated with an impressive growth rate CAGR over the forecasted period.

The National Center for Biotechnology Information emphasizes the pivotal role of Shingles vaccines in preventing the prevalence of herpes zoster, with an estimated 278 million cases expected globally in the coming decade in the absence of effective vaccination. The urgency for vaccine development is heightened, especially for immunocompromised patients, as existing antiviral treatments are not entirely effective for postherpetic neuralgia (PHN).

Shingles among Older Adults Driving Market Demand

Older adults, particularly those aged 60 and above, face an increased susceptibility to shingles due to weakened immune systems. The Centers for Disease Control and Prevention (CDC) reports that half of all shingles cases worldwide occur in this age group, emphasizing the need for a safe and cost-effective herpes zoster vaccine. Shingles, while not deadly, can lead to health complications such as pneumonia and encephalitis, making a vaccine crucial for this demographic.

Shingles Market Dynamics in Underdeveloped Countries

The prevalence of shingles varies based on geographical regions and prevailing climatic conditions. Shingles caused by the Varicella Zoster virus is common in tropical and subtropical regions. Underdeveloped countries, particularly in tropical Asia, lack routine varicella vaccination, presenting an opportunity for the shingles vaccine market. Integrating shingles vaccination programs into the WHO Regional Strategic Plan for Immunization in underdeveloped regions could significantly reduce disease burdens and associated complications.

Challenges and Impact of COVID-19 on Shingles Vaccine Market

Despite the positive outlook, challenges persist in developing effective shingles vaccines. The vaccine is typically administered before exposure to the Varicella Zoster virus, requiring strategic planning for efficacy. The latent reactivation of the virus in individuals with pre-existing immunity poses a challenge, necessitating the development of therapeutic vaccines for prompt immune response.

The COVID-19 pandemic had mixed effects on the Shingles vaccine market. Supply tensions and export bans initially disrupted vaccine rollouts, affecting sales. GlaxoSmithKline reported a significant drop in sales in the first quarter of 2021, attributed to disruptions caused by COVID-19 vaccine rollouts. However, the market rebounded in 2022, with GlaxoSmithKline's Shingles vaccine witnessing high revenue, reflecting a strong demand that outpaced supply after the pandemic.

Regional Growth and Market Analysis

Europe is emerging as a key growth region for the Shingles vaccine market, with the U.K. leading the way. The U.K. approved the shingles vaccine in its immunization program, achieving a vaccination rate of approximately 60%. Initiatives by key vaccine companies, such as GlaxoSmithKline plc., are contributing to the market's momentum. The expected growth rate in the European shingles market is estimated at 17% from 2024 to 2031, with an absolute dollar opportunity growth by 2032.

Country-Specific Insights

South Korea: The shingles vaccine market in South Korea is valued significantly in 2031. Revenue from shingles vaccines witnessed a substantial growth rate over the period from 2018 to 2023. Korean companies are actively expanding their presence in the global market with their shingles vaccines. Despite entering the shingles vaccine market relatively late, South Korea has achieved remarkable success, becoming the world's second-largest vaccine producer. SK Bioscience introduced Sky Zoster as a global solution for treating herpes zoster. SK Bioscience has also initiated efforts for the approval of 'Sky Zoster' in South Asian countries and is actively engaged in global clinical trials and expanding its product reach in the United States, China, and Europe. South Korea is expected to experience significant absolute dollar opportunity growth in the shingles vaccine market between 2024 and 2031.

China: China plays a prominent role in the shingles vaccine market, following the United States. The market in China holds substantial value in 2031 and is projected to witness substantial absolute dollar opportunity growth during the forecasted period. China achieved a notable growth rate in the shingles vaccine market from 2018 to 2023.

Competitive Analysis:

The competitive landscape showcases strategic developments by key players, positioning them for continued success in the dynamic vaccine market.

Key Companies Profiled

  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • SK Chemicals
  • Green Cross Corp
  • Geneone Life Science
  • Vaccitech
  • CanSinoBIO
  • Cipla Inc.
  • Pfizer Inc

Diverse Segments Explored in Comprehensive Shingles Vaccine Industry Study

Shingles Vaccine Market by Product Type:

  • Shingles
  • Zostavax
  • Sky Zoster

Shingles Vaccine Market by Vaccine Type:

  • Recombinant Vaccine
  • Live Attenuated Vaccine

Shingles Vaccine Market by Region:

  • North America Shingles Vaccine Market
  • Latin America Shingles Vaccine Market
  • Europe Shingles Vaccine Market
  • South Asia Shingles Vaccine Market
  • East Asia Shingles Vaccine Market
  • Oceania Shingles Vaccine Market
  • Middle East & Africa Shingles Vaccine Market

Table of Contents

1. Executive Summary

  • 1.1. Global Shingles Vaccine Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Shingles Vaccine Market Outlook, 2018 - 2031

  • 3.1. Global Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Shingles
      • 3.1.1.2. Zostavax
      • 3.1.1.3. Sky Zoster
  • 3.2. Global Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Recombinant Vaccine
      • 3.2.1.2. Live Attenuated Vaccine
  • 3.3. Global Shingles Vaccine Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Shingles Vaccine Market Outlook, 2018 - 2031

  • 4.1. North America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Shingles
      • 4.1.1.2. Zostavax
      • 4.1.1.3. Sky Zoster
  • 4.2. North America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Recombinant Vaccine
      • 4.2.1.2. Live Attenuated Vaccine
  • 4.3. North America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Shingles Vaccine Market Outlook, 2018 - 2031

  • 5.1. Europe Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Shingles
      • 5.1.1.2. Zostavax
      • 5.1.1.3. Sky Zoster
  • 5.2. Europe Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Recombinant Vaccine
      • 5.2.1.2. Live Attenuated Vaccine
  • 5.3. Europe Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Shingles Vaccine Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Shingles
      • 6.1.1.2. Zostavax
      • 6.1.1.3. Sky Zoster
  • 6.2. Asia Pacific Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Recombinant Vaccine
      • 6.2.1.2. Live Attenuated Vaccine
    • 6.2.2. BPS Analysis/Market Attractiveness Analysis
  • 6.3. Asia Pacific Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Shingles Vaccine Market Outlook, 2018 - 2031

  • 7.1. Latin America Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Shingles
      • 7.1.1.2. Zostavax
      • 7.1.1.3. Sky Zoster
  • 7.2. Latin America Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Recombinant Vaccine
      • 7.2.1.2. Live Attenuated Vaccine
    • 7.2.2. BPS Analysis/Market Attractiveness Analysis
  • 7.3. Latin America Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Shingles Vaccine Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Shingles Vaccine Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Shingles
      • 8.1.1.2. Zostavax
      • 8.1.1.3. Sky Zoster
  • 8.2. Middle East & Africa Shingles Vaccine Market Outlook, by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Recombinant Vaccine
      • 8.2.1.2. Live Attenuated Vaccine
    • 8.2.2. BPS Analysis/Market Attractiveness Analysis
  • 8.3. Middle East & Africa Shingles Vaccine Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Rest of Middle East & Africa Shingles Vaccine Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Shingles Vaccine Market by Vaccination Type, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Product vs by Vaccination Type Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. GlaxoSmithKline plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Therapy Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Merck & Co., Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Therapy Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. SK Chemicals
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Therapy Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Green Cross Corp
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Therapy Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Geneone Life Science
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Therapy Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Vaccitech
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Therapy Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. CanSinoBIO
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Therapy Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Cipla Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Therapy Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Pfizer Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Therapy Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations